聚乙二醇干扰素α-2a联合胸腺肽α1治疗慢性乙型肝炎随机对照观察

A Randomized Controlled Study of α-1-thymosin Combined with Peginterferon α-2a in the Treatment of Chronic Hepatit B

目的观察聚乙二醇干扰素α-2a(PEG INFα-2a)联合胸腺肽α1(Tα1)治疗慢性乙型肝炎(CHB)的疗效。方法将78例CHB患者随机分为聚乙二醇干扰素α-2a联合胸腺肽α1组和聚乙二醇干扰素α-2a组,观察两组的HBV DNA阴转率、ALT复常率、HBeAg阴转率、HBeAg/抗-HBe血清转换率的变化。结果治疗结束时联合组的HBVDNA阴转率、ALT复常率、HBeAg阴转率、HBeAg/抗-HBe血清转换率的改善均明显高于对照组(P<0.05)。随访6个月联合组的HBV DNA、HBeAg、抗-HBe等指标仍优于对照组(P<0.05)。结论聚乙二醇干扰素α-2a联合胸腺肽α1是治疗CHB的有效组合。

Objective To observe the efficacy of alpha-l-thymosin （ Tα1 ） eombind with peginterferon alpha-2a （ PEG INF α- 2a ）. Methods Seventy-eight patients with chronic hepatit B were randomly divided into PEG-INF α-2a＋Tα1 group and PEG- INF α-2a group, to ovserve the variations of HBV-DNA negative rate, ALT normalization, HBeAg negative rate, HBeAg/anti-HBe seroconversion. Results At the end of treatment, the HBV-DNA negative rate, ALT normalization, HBeAg negative rate, HBeAg/ anti-HBe seroconversion in combination group were higher than that in the PEG INFα-2a group, P 〈 0.05. During 6 months follow-up after treatment, the HBV-DNA negative rate, HBeAg negative rate, anti-HBe seroeonversion in combination group were significantly higher than that in the PEG INF α -2a group （P 〈 0.05 ）. Conclusion The Tα 1 eombind with PEG INF α -2a is an efficient methods to treat patients with chronic hepatit B.